

## What is the tomy's program?

### The tomy's program

- “tomy's” (Teva's Orphan hematological Malignancies award for Young hematologists and researchers) is an educational award program for young hematologists/researchers, organized by Teva Oncology
- Each year, the tomy's program will recognize young hematologists/researchers who can illustrate the latest scientific advances in the management of orphan hematological malignancies by presenting their research in a didactic and engaging manner, demonstrating their excellence in education and presentation skills
- The first award was presented during a Teva-organized symposium at ACUTE LEUKEMIAS XVI in Munich, Germany, in February 2017
- The final presentations for the second tomy's award will take place during a Teva-organized session at the 7<sup>th</sup> International Symposium on Acute Promyelocytic Leukemia, which will be held in Rome, Italy, from September 24 to 27, 2017

### Why is Teva Oncology organizing this initiative?

Teva Oncology is committed to encouraging young hematologists/researchers in the study of orphan hematological malignancies, and to working together towards the goal of understanding the pathophysiology and improving diagnosis and management of these rare hematological cancers.

### Who is on the tomy's jury?

The following experts in orphan hematological malignancies are all members of the 2017 tomy's jury:

- Pierre Fenaux, France
- Francesco Lo-Coco, Italy
- Bob Löwenberg, Netherlands
- Nigel Russell, UK
- Miguel Sanz, Spain
- Richard Schlenk, Germany

In subsequent years, the jury may feature other experts in the field of orphan hematological malignancies.

#### What will the tomy's finalists and winner receive?

The authors of the best abstracts (a maximum of 8) will be awarded travel and accommodation costs and registration fees to attend a European hematological congress; for the second tomy's award program this will be the 7<sup>th</sup> International Symposium on Acute Promyelocytic Leukemia in Rome, Italy, from September 24 to 27, 2017.

The authors of the top 4 abstracts will receive editorial support to develop an oral presentation to be given at a Teva-organized session during the main symposium.

The best presenter, judged both on content and presentation skills, will be chosen as the tomy's winner; he or she will be awarded the tomy's trophy, as well as travel and accommodation costs and registration fees for the American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA, USA, in December 2017.

The authors of the 4 next best abstracts will receive editorial, typesetting, and printing support to develop a poster to be presented at the main symposium.

## Call for Abstracts – The second tomy's award 2017

### General requirements and eligibility

- The first author should be a young hematologist/researcher, a physician training to become a hematologist, a PhD student or a PhD-level scientist; they should be aged 40 years or younger at the deadline for abstract submission
- Eligibility includes first authors affiliated to an institution in any country except the USA
- The abstract should report on one of the topics listed in the details for submissions to the 7<sup>th</sup> International Symposium on Acute Promyelocytic Leukemia (for more information see <http://www.apl2017.com/abstracts>)

### Abstract format

- The abstract format should follow the guidelines for the 7<sup>th</sup> International Symposium on Acute Promyelocytic Leukemia

### Abstract submission dates

- Abstracts can be submitted from March 1 2017 via the symposium website: <http://www.apl2017.com/abstracts>
- **The deadline for abstract submission is 11.59 PM (Pacific Daylight Time) on May 31, 2017**

### Responsibilities of the first author

- The first author listed for each abstract serves as the presenting author and as the primary contact for all tomy's correspondence, unless otherwise indicated in the "Comments" section of the online abstract submission form
- The first author is responsible for:
  - Ensuring that all authors have read the abstract and have agreed to be co-authors
  - Obtaining all conflict-of-interest disclosure and copyright transfer information from co-authors
  - Waiving any and all claims against Excerpta Medica and Teva Oncology and any reviewer arising from or relating to the abstract submission and review process, including but not limited to peer review and abstract evaluation

### **Additional information**

During the disclosure submission process you will also be required to indicate your compliance with the following:

- If you are providing recommendations involving clinical medicine, these recommendations will be based on evidence that is accepted within the medical profession as adequate justification for indication and contraindications of these medicines in patients care; all scientific research referred to in support of a patient–care recommendation will conform to generally accepted standards of experimental design, data collection, and analysis
- The content of the information with which you are involved will promote quality in health care or advances in science, and will not promote a specific proprietary or commercial interest; content for this publication will be well–balanced and unbiased
- If you have been trained or used by a commercial entity or its agents as a speaker (e.g. via participation in a speakers bureau) for any commercial interest, the promotional aspects of that work must not be included in the presentation in any way

### **Abstract review and selection**

- After the abstract deadline, all eligible abstracts will be made available to the jury for blinded review and scoring
- The score assigned by a jury member to an abstract submitted by an author from the same institution as the jury member will be disregarded
- Abstracts will be evaluated based on:
  - Scientific merit of the clinical case
  - Biological/clinical impact
- The jury will select the best abstracts (maximum of 8), irrespective of the category, based on the above criteria. The top 4 abstracts will be presented as oral presentations at a Teva–organized session during the 7<sup>th</sup> International Symposium on Acute Promyelocytic Leukemia in Rome, Italy, from September 24 to 27 2017. The remaining 4 abstracts will be developed as posters to be displayed in the Teva booth at the main symposium

- Oral presenters will be asked to submit slides (a maximum of 10) to Excerpta Medica by September 1, 2017; Excerpta Medica will provide editorial support for the presentation
- The poster presenters will receive typesetting and editorial support from Excerpta Medica; the content of the poster should be fully defined by the author in accordance with guidelines that will be provided, and should be submitted to Excerpta Medica by September 1, 2017, to allow sufficient time for preparation
- Excerpta Medica will contact the authors of abstracts selected for poster and/or oral presentations to make travel and accommodation arrangements

### **Acceptance/rejection notification**

- Notification regarding acceptance or rejection of abstracts will be sent by email to the presenting author before July 15, 2017; it is, therefore, vital that you provide the correct email address with your abstract submission
- If an abstract is accepted, the email will specify whether it has been selected as an oral or poster presentation

### **Abstract withdrawal**

- Once an abstract is selected, the presenter commits to attending the meeting

### **Further use of the abstracts**

- All selected abstracts will be published in an abstract book that will be made available to symposium attendees
- Teva Oncology reserves the right to use the case studies/case series in other educational and promotional materials

### **Contact information**

For queries regarding abstract submissions or notifications, please contact:  
[support@oncotomys.com](mailto:support@oncotomys.com)

HQ/ONCO/16/0142e